China
Africa
Explore chapters and articles related to this topic
Rosacea/Acne Rosacea
Published in Charles Theisler, Adjuvant Medical Care, 2023
Rosacea is a chronic inflammatory skin condition that causes redness and visible blood vessels on the cheeks, nose, chin, and forehead. It is more common among fair-skinned people and its cause is unknown. Small facial arteries under the skin tend to stay dilated, causing a tendency to blush or flush easily. Near the nose, cheeks, and eyes, over time, inflammatory papulopustular eruptions with red bumps and facial pustules (acne-like eruptions) develop. Skin becomes more coarse and thin threadlike red lines (telangiectasis) can develop. Rosacea is distinct from acne, but can be mistaken for acne or eczema.
Nanoparticle-Stabilized Liposomes as an Effective Bio-Active Drug Molecule Delivery for Acne Treatment
Published in Namrita Lall, Medicinal Plants for Cosmetics, Health and Diseases, 2022
Catherine Wilkinson, Marco N. De Canha, Namrita Lall
Acne is a relapsing condition that occurs primarily on the face, neck, chest and back, and is characterized by various physical manifestations appearing as comedones, nodules, pustules, papules and seborrhea (Garg, 2016; Holland et al., 1998; Simonart, 2012). The severity of acne is often determined by the presence of acne lesions of different morphologies, such as non-inflammatory lesions indicating a mild condition. This is often referred to as comedonal acne, characterized by open or closed comedones (commonly known as blackheads and/or whiteheads). Mild acne is often characterized by the presence of comedones with papules and pustules, and is referred to as papulopustular acne. In more severe cases, inflammatory lesions— including papules, pustules, nodules and cysts— may occur (Oon et al., 2019).
Acne, rosacea, and similar disorders
Published in Rashmi Sarkar, Anupam Das, Sumit Sethi, Concise Dermatology, 2021
Papulopustular rosacea: Most patients with active inflammatory lesions can be managed with topical therapies. Metronidazole (0.75%) gel or cream, azelaic acid (15%) gel, ivermectin(1%) cream and sulfacetamide (10%) with sulphur 5% preparations are the commonly used agents. Topical retinoids and benzoyl peroxide-clindamycin combinations have also been found useful. Systemic therapy is typically used in patients with unsatisfactory response to topical therapy. Tetracycline, doxycycline, and minocycline are the first-line antibiotics for papulopustular rosacea. In patients who cannot tolerate tetracyclines, alternative antibiotics include macrolides (erythromycin) and oral metroronidazole. Low-dose isotretinoin can be considered in resistant cases.
Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study
Published in Cutaneous and Ocular Toxicology, 2019
Basak Yalici-Armagan, Burcu Tugrul Ayanoglu, Hatice Gamze Demirdag
Pruritus was the most common symptom accompanying papulopustular rash that was seen in 20 (51.2%) patients. Four patients described burning or tenderness whereas fourteen patients were asymptomatic. Xerosis, paronychia, increased growth of the eyelashes, and mucositis were the other associated adverse cutaneous reactions that were seen in 7 (17.9%), 3 (7.6), 2 (5.1%), and 2 (5.1%) patients, respectively. Periungual pyogenic granuloma was accompanying with paronychia in one patient (2.5%). Bacterial superinfection was reported in two patients (5.1%). Clinical pictures of the patient number 24, who had bacterial superinfection, before (2a) and 2 weeks after (2b) initiation of therapy with topical mupirocin ointment and systemic doxycycline are shown in Figure 2. Hand-foot syndrome (HFS) was seen in one patient related with lapatinib–capecitabine combination. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) was another finding in one patient associated with cetuximab in combination with folinic acid, fluorouracil, and irinotecan hydrochloride (FOLFIRI) chemotherapy for metastatic rectum cancer (Figure 3).
Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX)
Published in OncoImmunology, 2020
David Tougeron, Sheik Emambux, Laure Favot, Thierry Lecomte, Ewa Wierzbicka-Hainaut, Mahtab Samimi, Eric Frouin, Nicolas Azzopardi, Jocelyn Chevrier, Laura Serres, Julie Godet, Pierre Levillain, Gilles Paintaud, Aurélie Ferru, Laetitia Rouleau, Adriana Delwail, Christine Silvain, Jean-Pierre Tasu, Franck Morel, Stéphanie Ragot, Jean-Claude Lecron
EGFR is a transmembrane glycoprotein, one of the four members of the ErbB family of tyrosine kinase receptors, over-expressed in many cancers, especially in 60–80% of mCRC.8–12 EGFR is an inactive monomer on its own and is activated after ligand binding and dimerization. This activates the intracellular tyrosine kinase region of EGFR, resulting in the initiation of a signaling pathway involved in cell differentiation, proliferation, migration, angiogenesis, apoptosis and metastatic spread.13 Cetuximab is a chimeric IgG1 mAb that binds specifically to the external domain of EGFR and blocks ligand binding and receptor activation.13 Several studies have shown the efficacy of cetuximab in mCRC, as monotherapy or combined with chemotherapy, but only in RAS wild-type tumors.8,14,15 Cetuximab can cause mostly manageable infusion-related hypersensitivity reactions in approximately 15% of patients,16 but the most common adverse event is a papulopustular rash.17 This skin reaction is found in 60% to 80% of patients treated with an anti-EGFR mAb with 8% to 17% having grade 3 or 4 skin toxicity.7,8,18 Other forms of skin reaction include dry skin, pruritus, erythema and paronychia. The papulopustular rash generally occurs between one and three weeks after treatment initiation and usually involves the face and upper torso.17 Several studies have demonstrated a positive correlation between the papulopustular rash and tumor response and/or survival in mCRC patients treated with anti-EGFR therapy.8,19 For example, Cunningham et al. showed that the response rate to cetuximab in mCRC was 55.2% when the skin reaction was severe compared to 6.3% in the absence of skin reaction.8
Clinical phenotypes of Behçet’s syndrome in a large cohort of Italian patients: focus on gender differences
Published in Scandinavian Journal of Rheumatology, 2021
P Leccese, MC Padula, N Lascaro, AA Padula, S D’Angelo
With regard to papulopustular lesions, the predominance of these skin manifestations in males has been reported previously (5, 11, 13, 14). Ocular involvement was found in less than 60% in the whole series. A higher frequency of posterior uveitis/retinitis and panuveitis was observed in male patients. These data were similar to the findings of Pipitone et al (5). A higher prevalence of ocular involvement in males was also a common literature finding in Korean, Japanese, Spanish, and Turkish populations (6, 10–14).